Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | GNAI3 | P08754 | 4/20 | 0.36 |
| ▸ | GNAI1 | P63096 | 4/20 | 0.36 |
| ▸ | GNAO1 | P09471 | 3/20 | 0.35 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.34 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.34 |
| ▸ | NAMPT | P43490 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23594448 | 0.83 | L3MBTL1 (0.44) | L3MBTL1MEN1KMT2ATDP1ATM | |
| SCHEMBL21946798 | 0.82 | L3MBTL1 (0.39) | L3MBTL1MEN1KMT2ATDP1ATM | |
| SCHEMBL24926275 | 0.82 | L3MBTL1 (0.39) | L3MBTL1MEN1KMT2ATDP1ATM | |
| SCHEMBL8972662 | 0.81 | GNAI3 (0.51) | L3MBTL1MEN1KMT2ATDP1ATM | |
| SCHEMBL21016150 | 0.80 | L3MBTL1 (0.63) | L3MBTL1MEN1KMT2ATDP1ATM | |
| SCHEMBL26827452 | 0.79 | GAA (0.36) | LMNAMAPT | |
| SCHEMBL21016203 | 0.78 | L3MBTL1 (0.65) | L3MBTL1MEN1KMT2ATDP1ATM | |
| SCHEMBL5654305 | 0.78 | L3MBTL1 (0.61) | L3MBTL1MEN1KMT2ATDP1ATM | |
| SCHEMBL5652742 | 0.77 | L3MBTL1 (0.62) | L3MBTL1MEN1KMT2ATDP1ATM | |
| SCHEMBL21946392 | 0.76 | KDM1A (0.39) | ATMNPC1GNAI3GNAI1GNAO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230029378-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS, INC. | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230029378-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | CBL, XIAP, BTK | L3MBTL1 857/4885MEN1 3115/4885KMT2A 1161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.